GRI-0621 an oral, RARβ/γ-selective investigational therapy designed to modulate pathways involved in inflammation and fibrosis in IPF. Emerging scientific evidence increasingly supports the role of ...

The Global Reporting Initiative is responding to a proposal from the International Financial Reporting Standards Foundation to oversee sustainability standards alongside international accounting ...

GRI Bio ( (GRI)) has issued an announcement. On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...

The International Financial Reporting Standards Foundation and the Global Reporting Initiative said Thursday they have reached a collaboration agreement to coordinate their standard-setting and work ...

GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

Seth Engel, Olga Gidalevitz Ph.D. The Global Reporting Initiative (GRI) published two new topic standards—GRI 102: Climate Change (2025) and GRI 103: Energy (2025). These standards will replace GRI ...

Short interest in GRI Bio Inc (NASDAQ:GRI) increased during the last reporting period, rising from 142.33K to 383.63K. This put 6.53% of the company's publicly available shares short. Based on the ...

The revision came at an unprecedented time. The COVID-19 pandemic highlighted many gaps in understanding the impact of our supply chains on social structures and communities; revealing deep inequities ...